Giancarlo Agnelli Selected Research

Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)

1/2022	Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
5/2021	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
10/2020	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis.
7/2020	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
1/2020	Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life.
1/2020	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis.
1/2020	Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY.
1/2019	Anticoagulation After Stroke in Patients With Atrial Fibrillation.
10/2018	Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis.
9/2018	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giancarlo Agnelli Research Topics

Disease

92	Hemorrhage 07/2022 - 07/2002
85	Venous Thromboembolism 07/2022 - 03/2002
61	Neoplasms (Cancer) 05/2022 - 03/2002
52	Stroke (Strokes) 01/2022 - 01/2004
42	Atrial Fibrillation 01/2022 - 01/2004
41	Pulmonary Embolism 01/2022 - 12/2002
36	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 10/2003
26	Ischemic Stroke 01/2022 - 01/2007
22	Thrombosis (Thrombus) 02/2022 - 01/2002
11	Acute Coronary Syndrome 08/2015 - 01/2005
6	Thrombocytopenia (Thrombopenia) 07/2021 - 07/2002
6	Cerebral Hemorrhage 01/2021 - 01/2007
6	Myocardial Infarction 01/2020 - 01/2004
6	Embolism (Embolus) 12/2019 - 03/2012
5	Body Weight (Weight, Body) 05/2021 - 10/2011
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 05/2022 - 01/2020
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 06/2007
4	Hematoma 01/2020 - 08/2008
4	Heart Diseases (Heart Disease) 01/2019 - 01/2007
4	Embolic Stroke 01/2019 - 02/2007
4	Thromboembolism 04/2016 - 01/2005
4	Transient Ischemic Attack 08/2015 - 01/2007
4	ST Elevation Myocardial Infarction 06/2010 - 06/2005
3	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 09/2017
3	Brain Neoplasms (Brain Tumor) 01/2022 - 05/2021
3	Shock 11/2020 - 07/2007
3	Vascular Diseases (Vascular Disease) 08/2015 - 01/2007
3	Clinical Deterioration 11/2013 - 10/2008
3	Hemorrhagic Stroke 01/2013 - 11/2009
3	Unstable Angina 06/2007 - 07/2002
2	Renal Insufficiency (Renal Failure) 01/2022 - 01/2020
2	Hematologic Neoplasms (Hematological Malignancy) 07/2021 - 01/2013
2	Lung Neoplasms (Lung Cancer) 10/2020 - 01/2018
2	Infections 12/2019 - 01/2013
2	Hypertension (High Blood Pressure) 11/2019 - 01/2012
2	Brain Ischemia (Cerebral Ischemia) 01/2019 - 03/2012
2	Wounds and Injuries (Trauma) 10/2016 - 06/2002
2	Right Ventricular Dysfunction 04/2014 - 11/2013

Drug/Important Bio-Agent (IBA)

113	AnticoagulantsIBA 07/2022 - 07/2003
29	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2022 - 07/2002
26	Heparin (Liquaemin)FDA LinkGeneric 10/2020 - 07/2002
24	Vitamin K FDA Link 07/2021 - 01/2005
21	apixabanIBA 05/2022 - 03/2012
21	RivaroxabanIBA 01/2022 - 07/2007
18	Warfarin (Coumadin)FDA LinkGeneric 12/2020 - 07/2007
15	Enoxaparin (Lovenox)FDA LinkGeneric 01/2020 - 03/2002
11	edoxabanIBA 01/2022 - 07/2014
11	Factor Xa InhibitorsIBA 01/2022 - 07/2007
11	Dabigatran FDA Link 02/2020 - 05/2010
10	Dalteparin (Dalteparin Sodium)FDA Link 05/2022 - 09/2018
10	Pharmaceutical PreparationsIBA 07/2021 - 01/2005
8	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020 - 06/2005
7	TroponinIBA 01/2021 - 07/2007
7	AntithrombinsIBA 06/2012 - 02/2003
6	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 01/2002
6	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021 - 01/2007
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016 - 06/2005
5	Thrombin FDA Link 06/2013 - 01/2004
5	ximelagatran (Exanta)IBA 01/2006 - 02/2003
4	factor V LeidenIBA 01/2015 - 09/2002
4	Blood Glucose (Blood Sugar)IBA 03/2012 - 08/2008
4	melagatranIBA 01/2006 - 02/2003
3	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2019 - 01/2013
3	LDL Lipoproteins (beta Lipoproteins)IBA 01/2018 - 01/2007
3	LDL CholesterolIBA 01/2018 - 01/2007
3	CholesterolIBA 01/2016 - 01/2007
3	Factor Xa (Coagulation Factor Xa)IBA 06/2013 - 04/2012
3	Biomarkers (Surrogate Marker)IBA 09/2012 - 01/2009
3	Fibrinolytic Agents (Antithrombotic Agents)IBA 04/2012 - 07/2002
3	Nadroparin (Nadroparin Calcium)IBA 10/2011 - 10/2009
3	Prothrombin (Factor II)IBA 05/2009 - 09/2002
3	Glycoproteins (Glycoprotein)IBA 01/2009 - 11/2005
2	Hemoglobins (Hemoglobin)IBA 10/2021 - 11/2020
2	CreatinineIBA 10/2021 - 01/2020
2	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 05/2014
2	Antihypertensive Agents (Antihypertensives)IBA 11/2019 - 01/2011
2	Progestins (Progestagens)IBA 06/2018 - 04/2008
2	oxidized low density lipoproteinIBA 01/2018 - 09/2007
2	semuloparinIBA 06/2014 - 02/2012
2	Tenecteplase FDA Link 04/2014 - 03/2010
2	Fondaparinux (Arixtra)FDA Link 03/2012 - 06/2008
2	fibrin fragment D (D-dimer)IBA 01/2012 - 02/2008

Therapy/Procedure

62	Therapeutics 07/2022 - 07/2003
15	Drug Therapy (Chemotherapy) 02/2022 - 10/2003
11	Secondary Prevention 01/2022 - 01/2004
10	Length of Stay 01/2021 - 01/2007
9	Catheters 02/2022 - 06/2005
8	Thrombolytic Therapy 01/2020 - 08/2004
5	Central Venous Catheters 12/2019 - 10/2003
4	Duration of Therapy 07/2022 - 07/2003
4	Orthopedic Procedures 12/2017 - 07/2002
3	Percutaneous Coronary Intervention 10/2018 - 06/2010
3	Vena Cava Filters (Inferior Vena Cava Filter) 12/2016 - 02/2008
3	Hip Replacement Arthroplasty (Total Hip Replacement) 02/2014 - 07/2002
3	Subcutaneous Injections 10/2011 - 07/2002
2	Oral Administration 07/2021 - 09/2008
2	Contraindications 01/2020 - 06/2018
2	Activities of Daily Living (ADL) 01/2018 - 01/2012
2	Bed Rest (Bedrest) 09/2016 - 01/2006
2	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2015 - 04/2008